ERCC1-expresszió vizsgálata platinabázisú kezelésben részesülo{double acute} tüdo{double acute}rákos betegekben

Translated title of the contribution: Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy

Judit Moldvay, Judit Pápay, Rita Puskás, József Furák, G. Losonczy, A. Matolcsy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Platinum-based chemotherapies are widely used in the treatment of lung cancer. However, little is known about their effect in the expression of certain tissue biomarkers. We have studied the ERCC1 (excision repair cross-complementation group 1) expression in tissue samples of patients treated with neoadjuvant chemotherapy. Fifty lung cancer tissue blocks of 25 patients (15 males, 10 females) were studied. They included 25 bronchoscopic biopsies (14 squamous cell carcinomas and 11 adenocarcinomas) together with their corresponding surgical biopsies after neoadjuvant chemotherapy. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues to study the expression of ERCC1. Staining scores (0-300) were calculated by multiplying the percentage of positive tumor cells (0-100) by the staining intensity (0-3). All but one bronchosopic squamous cell carcinoma tissues (13/14) expressed ERCC1. Four of these cases became negative after neoadjuvant therapy, and in 8 cases the level of expression decreased. In the adenocarcinoma group all but one bronchosopic tissues (10/11) expressed ERCC1. Six of these cases became negative after neoadjuvant therapy, and in 4 cases the level of expression decreased. Comparison of staining scores before and after chemotherapy revealed more pronounced decrease in adenocarcinomas and in female patients. There was no newly expressed ERCC1-positive case in the surgical biopsy group. The results of the present study suggest that platinum-based chemotherapy affects the expression of tissue biomarker (ERCC1) which may have predictive value, and probably induces a selection of tumor cells with more aggressive phenotype. This knowledge might be of importance when designing treatment protocols for non-small cell lung cancer patients.

Original languageHungarian
Pages (from-to)105-109
Number of pages5
JournalMagyar Onkologia
Volume55
Issue number2
Publication statusPublished - 2011

Fingerprint

Platinum
DNA Repair
Lung Neoplasms
Drug Therapy
Adenocarcinoma
Neoadjuvant Therapy
Staining and Labeling
Biopsy
Squamous Cell Carcinoma
Biomarkers
Clinical Protocols
Non-Small Cell Lung Carcinoma
Paraffin
Formaldehyde
Neoplasms
Immunohistochemistry
Phenotype

ASJC Scopus subject areas

  • Oncology

Cite this

ERCC1-expresszió vizsgálata platinabázisú kezelésben részesülo{double acute} tüdo{double acute}rákos betegekben. / Moldvay, Judit; Pápay, Judit; Puskás, Rita; Furák, József; Losonczy, G.; Matolcsy, A.

In: Magyar Onkologia, Vol. 55, No. 2, 2011, p. 105-109.

Research output: Contribution to journalArticle

@article{103bbf85ab5c45dc8bef73418f70f3b3,
title = "ERCC1-expresszi{\'o} vizsg{\'a}lata platinab{\'a}zis{\'u} kezel{\'e}sben r{\'e}szes{\"u}lo{double acute} t{\"u}do{double acute}r{\'a}kos betegekben",
abstract = "Platinum-based chemotherapies are widely used in the treatment of lung cancer. However, little is known about their effect in the expression of certain tissue biomarkers. We have studied the ERCC1 (excision repair cross-complementation group 1) expression in tissue samples of patients treated with neoadjuvant chemotherapy. Fifty lung cancer tissue blocks of 25 patients (15 males, 10 females) were studied. They included 25 bronchoscopic biopsies (14 squamous cell carcinomas and 11 adenocarcinomas) together with their corresponding surgical biopsies after neoadjuvant chemotherapy. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues to study the expression of ERCC1. Staining scores (0-300) were calculated by multiplying the percentage of positive tumor cells (0-100) by the staining intensity (0-3). All but one bronchosopic squamous cell carcinoma tissues (13/14) expressed ERCC1. Four of these cases became negative after neoadjuvant therapy, and in 8 cases the level of expression decreased. In the adenocarcinoma group all but one bronchosopic tissues (10/11) expressed ERCC1. Six of these cases became negative after neoadjuvant therapy, and in 4 cases the level of expression decreased. Comparison of staining scores before and after chemotherapy revealed more pronounced decrease in adenocarcinomas and in female patients. There was no newly expressed ERCC1-positive case in the surgical biopsy group. The results of the present study suggest that platinum-based chemotherapy affects the expression of tissue biomarker (ERCC1) which may have predictive value, and probably induces a selection of tumor cells with more aggressive phenotype. This knowledge might be of importance when designing treatment protocols for non-small cell lung cancer patients.",
keywords = "ERCC1 protein expression, Immunohistochemistry, Neoadjuvant treatment, Non-small cell lung cancer, Predictive factors",
author = "Judit Moldvay and Judit P{\'a}pay and Rita Pusk{\'a}s and J{\'o}zsef Fur{\'a}k and G. Losonczy and A. Matolcsy",
year = "2011",
language = "Hungarian",
volume = "55",
pages = "105--109",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - ERCC1-expresszió vizsgálata platinabázisú kezelésben részesülo{double acute} tüdo{double acute}rákos betegekben

AU - Moldvay, Judit

AU - Pápay, Judit

AU - Puskás, Rita

AU - Furák, József

AU - Losonczy, G.

AU - Matolcsy, A.

PY - 2011

Y1 - 2011

N2 - Platinum-based chemotherapies are widely used in the treatment of lung cancer. However, little is known about their effect in the expression of certain tissue biomarkers. We have studied the ERCC1 (excision repair cross-complementation group 1) expression in tissue samples of patients treated with neoadjuvant chemotherapy. Fifty lung cancer tissue blocks of 25 patients (15 males, 10 females) were studied. They included 25 bronchoscopic biopsies (14 squamous cell carcinomas and 11 adenocarcinomas) together with their corresponding surgical biopsies after neoadjuvant chemotherapy. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues to study the expression of ERCC1. Staining scores (0-300) were calculated by multiplying the percentage of positive tumor cells (0-100) by the staining intensity (0-3). All but one bronchosopic squamous cell carcinoma tissues (13/14) expressed ERCC1. Four of these cases became negative after neoadjuvant therapy, and in 8 cases the level of expression decreased. In the adenocarcinoma group all but one bronchosopic tissues (10/11) expressed ERCC1. Six of these cases became negative after neoadjuvant therapy, and in 4 cases the level of expression decreased. Comparison of staining scores before and after chemotherapy revealed more pronounced decrease in adenocarcinomas and in female patients. There was no newly expressed ERCC1-positive case in the surgical biopsy group. The results of the present study suggest that platinum-based chemotherapy affects the expression of tissue biomarker (ERCC1) which may have predictive value, and probably induces a selection of tumor cells with more aggressive phenotype. This knowledge might be of importance when designing treatment protocols for non-small cell lung cancer patients.

AB - Platinum-based chemotherapies are widely used in the treatment of lung cancer. However, little is known about their effect in the expression of certain tissue biomarkers. We have studied the ERCC1 (excision repair cross-complementation group 1) expression in tissue samples of patients treated with neoadjuvant chemotherapy. Fifty lung cancer tissue blocks of 25 patients (15 males, 10 females) were studied. They included 25 bronchoscopic biopsies (14 squamous cell carcinomas and 11 adenocarcinomas) together with their corresponding surgical biopsies after neoadjuvant chemotherapy. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues to study the expression of ERCC1. Staining scores (0-300) were calculated by multiplying the percentage of positive tumor cells (0-100) by the staining intensity (0-3). All but one bronchosopic squamous cell carcinoma tissues (13/14) expressed ERCC1. Four of these cases became negative after neoadjuvant therapy, and in 8 cases the level of expression decreased. In the adenocarcinoma group all but one bronchosopic tissues (10/11) expressed ERCC1. Six of these cases became negative after neoadjuvant therapy, and in 4 cases the level of expression decreased. Comparison of staining scores before and after chemotherapy revealed more pronounced decrease in adenocarcinomas and in female patients. There was no newly expressed ERCC1-positive case in the surgical biopsy group. The results of the present study suggest that platinum-based chemotherapy affects the expression of tissue biomarker (ERCC1) which may have predictive value, and probably induces a selection of tumor cells with more aggressive phenotype. This knowledge might be of importance when designing treatment protocols for non-small cell lung cancer patients.

KW - ERCC1 protein expression

KW - Immunohistochemistry

KW - Neoadjuvant treatment

KW - Non-small cell lung cancer

KW - Predictive factors

UR - http://www.scopus.com/inward/record.url?scp=80051717052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051717052&partnerID=8YFLogxK

M3 - Article

C2 - 21655476

AN - SCOPUS:80051717052

VL - 55

SP - 105

EP - 109

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -